Brit J Heamatol:实体恶性肿瘤患者中肝素诱导的血小板减少症发生率和预后

2020-05-02 MedSci原创 MedSci原创

HIT在实体恶性肿瘤患者中是一种罕见病,但会增加这类患者的发病率和死亡率。

肝素诱导的血小板减少症(HIT)是机体对肝素产品出现的免疫介导的不良反应,其特征是伴有或不伴有血栓形成的血小板减少症。近日,血液系统疾病权威杂志British Journal of Haematology上发表了一篇研究文章,该研究旨在明确与实体恶性肿瘤相关的住院治疗中HIT的发生率、发病率、死亡率和经济负担。

研究人员分析了2012年1月至2015年9月期间美国最大的住院病人公共数据库-国家住院样本数据库(NIS)。该研究的主要结局是HIT的发生率,次要结局包括静脉血栓形成(急性深静脉血栓形成和肺栓塞)、动脉血栓形成(血栓性卒中、心肌梗塞和其他动脉血栓栓塞)、与HIT相关的死亡率、住院时间、总住院费用和处置情况。

在研究期间,有7437049例住院诊断为实体恶性肿瘤。在该人群中,约0.08%(n=6225)住院患者次要诊断中有HIT。与没有HIT的实体恶性肿瘤患者相比,伴有HIT的实体恶性肿瘤患者总血栓事件的标准化发生率更高(24.7% vs. 6.8%,P<0.001)。伴有HIT的实体恶性肿瘤患者标准死亡率为4.8%,而不伴有HIT的实体恶性肿瘤患者标准死亡率为3.4%(OR为1.53;95%CI为1.25-1.89;P<0.001)。

由此可见,HIT在实体恶性肿瘤患者中是一种罕见病,但会增加这类患者的发病率和死亡率。

原始出处:

Rohit Kumar.et al.Incidence and outcomes of heparin‐induced thrombocytopenia in solid malignancy: an analysis of the National Inpatient Sample Database.british journal of haematology.2020.https://onlinelibrary.wiley.com/doi/10.1111/bjh.16400

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826607, encodeId=539f182660e07, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Nov 14 08:11:39 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302845, encodeId=34851302845e4, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon May 04 06:11:39 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424315, encodeId=dbc9142431554, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Mon May 04 06:11:39 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540611, encodeId=2f751540611c3, content=<a href='/topic/show?id=4aa88133972' target=_blank style='color:#2F92EE;'>#肝素诱导的血小板减少症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81339, encryptionId=4aa88133972, topicName=肝素诱导的血小板减少症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43b613270021, createdName=kkunny, createdTime=Mon May 04 06:11:39 CST 2020, time=2020-05-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1826607, encodeId=539f182660e07, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Nov 14 08:11:39 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302845, encodeId=34851302845e4, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon May 04 06:11:39 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424315, encodeId=dbc9142431554, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Mon May 04 06:11:39 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540611, encodeId=2f751540611c3, content=<a href='/topic/show?id=4aa88133972' target=_blank style='color:#2F92EE;'>#肝素诱导的血小板减少症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81339, encryptionId=4aa88133972, topicName=肝素诱导的血小板减少症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43b613270021, createdName=kkunny, createdTime=Mon May 04 06:11:39 CST 2020, time=2020-05-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1826607, encodeId=539f182660e07, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Nov 14 08:11:39 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302845, encodeId=34851302845e4, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon May 04 06:11:39 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424315, encodeId=dbc9142431554, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Mon May 04 06:11:39 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540611, encodeId=2f751540611c3, content=<a href='/topic/show?id=4aa88133972' target=_blank style='color:#2F92EE;'>#肝素诱导的血小板减少症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81339, encryptionId=4aa88133972, topicName=肝素诱导的血小板减少症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43b613270021, createdName=kkunny, createdTime=Mon May 04 06:11:39 CST 2020, time=2020-05-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1826607, encodeId=539f182660e07, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Nov 14 08:11:39 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302845, encodeId=34851302845e4, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon May 04 06:11:39 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424315, encodeId=dbc9142431554, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Mon May 04 06:11:39 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540611, encodeId=2f751540611c3, content=<a href='/topic/show?id=4aa88133972' target=_blank style='color:#2F92EE;'>#肝素诱导的血小板减少症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81339, encryptionId=4aa88133972, topicName=肝素诱导的血小板减少症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43b613270021, createdName=kkunny, createdTime=Mon May 04 06:11:39 CST 2020, time=2020-05-04, status=1, ipAttribution=)]

相关资讯

Sci Rep:手术切除的食管鳞状细胞癌

对于可手术切除的eSCC患者,在PET/CT时测量原发肿瘤的SUVmax可以帮助预测患者的生存率。

Crit Care:液体复苏输液速率对脓毒症性休克患者预后的影响

在脓毒症性休克患者中,与输液速度较慢相比,液体复苏速率为0.25-0.50 ml/kg/min(即,在最初的2h内完成30 ml/kg的静脉液体复苏)可能与早期休克逆转和降低28天死亡率相关。

Sci Rep:血清高迁移率族蛋白-1浓度在心脏手术中的预后作用

鉴于其在无菌炎症的介导中起重要作用及与不良结局的关联,脱离CPB 1小时后测得的HMGB1可作为心脏手术患者进行准确风险分层的有用生物标志物,并可指导个性化的抗炎治疗。

Heart:基于深度学习图像分析的法洛四联症预后预测

这项研究提供了关于使用外部影像数据集训练的机器学习算法效用的数据,其可以自动估计ToF患者的预后。

Heart:严重主动脉瓣狭窄患者主动脉瓣置换后的左心室充盈压和生存率

接受AVR的AS患者术前左心室充盈压升高是常见现象,无论其症状如何,均具有重要的预后意义。

Clin Gastroenterol H:结肠息肉切除术后30天内出血的处理和预后

DPPB患者经常过度使用了结肠镜检查。研究人员确定了活动性出血的独立危险因素,可用于确定最有可能从结肠镜检查中受益的患者。